Sandra Swain
Sandra Swain
Verified email at
Cited by
Cited by
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond, EA Perez, J Bryant, VJ Suman, CE Geyer Jr, NE Davidson, ...
New England journal of medicine 353 (16), 1673-1684, 2005
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino, N Wolmark, ...
The Lancet 384 (9938), 164-172, 2014
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
J Baselga, J Cortés, SB Kim, SA Im, R Hegg, YH Im, L Roman, JL Pedrini, ...
New England Journal of Medicine 366 (2), 109-119, 2012
Congestive heart failure in patients treated with doxorubicin A retrospective analysis of three trials
SM Swain, FS Whaley, MS Ewer
Cancer: Interdisciplinary International Journal of the American Cancer …, 2003
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
SM Swain, J Baselga, SB Kim, J Ro, V Semiglazov, M Campone, ...
New England journal of medicine 372 (8), 724-734, 2015
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 379 (9814), 432-444, 2012
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women …
DLW Kwong, P McGale, C Taylor, C Correa, D Cutter, F Duane, M Ewertz, ...
The Lancet, 2014
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
J Baselga, SM Swain
Nature Reviews Cancer 9 (7), 463-475, 2009
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo …
SM Swain, SB Kim, J Cortés, J Ro, V Semiglazov, M Campone, E Ciruelos, ...
The lancet oncology 14 (6), 461-471, 2013
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG …
EA Perez, EH Romond, VJ Suman, JH Jeong, G Sledge, CE Geyer Jr, ...
Journal of clinical oncology 32 (33), 3744, 2014
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in …
E Tan-Chiu, G Yothers, E Romond, CE Geyer Jr, M Ewer, D Keefe, ...
Journal of Clinical Oncology 23 (31), 7811-7819, 2005
3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3)
F Cardoso, A Costa, E Senkus, M Aapro, F André, CH Barrios, J Bergh, ...
The Breast 31, 244-259, 2017
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
B Asselain, W Barlow, J Bartlett, J Bergh, E Bergsten-Nordström, J Bliss, ...
The Lancet Oncology 19 (1), 27-39, 2018
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS
IL Wapnir, JJ Dignam, B Fisher, EP Mamounas, SJ Anderson, TB Julian, ...
Journal of the National Cancer Institute 103 (6), 478-488, 2011
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
SM Swain, FS Whaley, MC Gerber, S Weisberg, M York, D Spicer, ...
Journal of Clinical Oncology 15 (4), 1318-1332, 1997
Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells
KA West, J Brognard, AS Clark, IR Linnoila, X Yang, SM Swain, C Harris, ...
The Journal of clinical investigation 111 (1), 81-90, 2003
Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials
C Taylor, C Correa, FK Duane, MC Aznar, SJ Anderson, J Bergh, ...
Journal of Clinical Oncology 35 (15), 1641, 2017
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
SB Wedam, JA Low, SX Yang, CK Chow, P Choyke, D Danforth, ...
Journal of Clinical Oncology 24 (5), 769-777, 2006
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The lancet oncology 18 (12), 1688-1700, 2017
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 386 (10001), 1353-1361, 2015
The system can't perform the operation now. Try again later.
Articles 1–20